[A18-76] Pertuzumab (breast cancer) - Addendum to Commission A18-41
Last updated 20.12.2018
Commission awarded on 05.11.2018 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy
Conclusion of dossier assessment A18-41 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.